[go: up one dir, main page]

EA200701218A1 - Композиция для лечения ретинол-ассоциированных заболеваний - Google Patents

Композиция для лечения ретинол-ассоциированных заболеваний

Info

Publication number
EA200701218A1
EA200701218A1 EA200701218A EA200701218A EA200701218A1 EA 200701218 A1 EA200701218 A1 EA 200701218A1 EA 200701218 A EA200701218 A EA 200701218A EA 200701218 A EA200701218 A EA 200701218A EA 200701218 A1 EA200701218 A1 EA 200701218A1
Authority
EA
Eurasian Patent Office
Prior art keywords
retinol
methods
treatment
compositions
present
Prior art date
Application number
EA200701218A
Other languages
English (en)
Other versions
EA010827B1 (ru
Inventor
Кеннет Уиддер
Джэй Личтер
Original Assignee
Сирион Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сирион Терапьютикс, Инк. filed Critical Сирион Терапьютикс, Инк.
Publication of EA200701218A1 publication Critical patent/EA200701218A1/ru
Publication of EA010827B1 publication Critical patent/EA010827B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение относится к способам и композициям для лечения определенных ретинол-ассоциированных заболеваний и состояний путем модуляции доступности транстиретина (TTR, от англ. Transthyretin) и ретинол-связывающего белка (RBP, от англ. Retinol Binding Protein) у пациента. Например, заявленные способы и композиции относятся к терапевтическим агентам для лечения и/или профилактики возрастной макулярной дегенерации и/или дистрофии, метаболических нарушений, идиопатической внутричерепной гипертензии, гиперостоза, а также заболеваний, ассоциированных с неправильной укладкой белков или их накоплением. Композиции, заявленные в соответствии с настоящим изобретением, могут использоваться как самостоятельно, так и в комбинации с другими агентами и способами лечения. Кроме того, настоящее изобретение относится к способам поиска и исследованиям подходящих агентов, которые могут влиять на доступность TTR и RBP у пациента.
EA200701218A 2004-12-08 2005-12-07 Композиции для лечения ретинол-ассоциированных заболеваний EA010827B1 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US63444904P 2004-12-08 2004-12-08
US66092405P 2005-03-10 2005-03-10
US66090405P 2005-03-11 2005-03-11
US67240505P 2005-04-18 2005-04-18
US69851205P 2005-07-11 2005-07-11
PCT/US2005/044416 WO2006063128A2 (en) 2004-12-08 2005-12-07 Methods, assays and compositions for treating retinol-related diseases

Publications (2)

Publication Number Publication Date
EA200701218A1 true EA200701218A1 (ru) 2007-10-26
EA010827B1 EA010827B1 (ru) 2008-12-30

Family

ID=35735778

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200701218A EA010827B1 (ru) 2004-12-08 2005-12-07 Композиции для лечения ретинол-ассоциированных заболеваний
EA200701828A EA011154B1 (ru) 2004-12-08 2005-12-07 Композиции для лечения ретинол-ассоциированных заболеваний

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200701828A EA011154B1 (ru) 2004-12-08 2005-12-07 Композиции для лечения ретинол-ассоциированных заболеваний

Country Status (18)

Country Link
US (3) US20060135460A1 (ru)
EP (3) EP1827407A4 (ru)
JP (3) JP4178281B2 (ru)
KR (2) KR100971695B1 (ru)
CN (3) CN102240278A (ru)
AU (3) AU2005314039B2 (ru)
BR (2) BRPI0518616A (ru)
CA (2) CA2584845C (ru)
EA (2) EA010827B1 (ru)
GB (1) GB2421433B (ru)
GE (1) GEP20094644B (ru)
IL (2) IL182837A0 (ru)
LV (1) LV13666B (ru)
MX (1) MX2007006245A (ru)
NO (2) NO20073510L (ru)
NZ (2) NZ561148A (ru)
SG (1) SG144145A1 (ru)
WO (1) WO2006063128A2 (ru)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
JP4869942B2 (ja) 2003-12-11 2012-02-08 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド インスリン感受性／抵抗性、糖尿病および肥満におけるｒｂｐ４
US7512436B2 (en) * 2004-02-12 2009-03-31 The Regents Of The University Of Michigan Method of evaluating metabolism of the eye
RU2006133300A (ru) * 2004-02-17 2008-03-27 Президент Энд Феллоуз Оф Гарвард Колледж (Us) Управление течением офтальмологических расстройств, включая дегенерацию желтого пятна
JP2007525496A (ja) * 2004-02-17 2007-09-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 黄班変性症を含む眼科疾患の管理
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
DK1725234T4 (en) * 2004-03-05 2016-05-09 Univ Pennsylvania METHODS OF TREATING DISEASES OR DISEASES CONNECTED WITH HYPERLIPIDEMIA AND HYPERCOLESTEROLYMIA WITH MINIMIZATION OF SIDE EFFECTS
GEP20084520B (en) 2004-06-23 2008-10-27 Sirion Therapeutics Inc Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
CA2584396A1 (en) * 2004-11-04 2006-05-18 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation
CN102240278A (zh) * 2004-12-08 2011-11-16 矫正诊疗公司 治疗与视黄醇有关的疾病的方法、分析和组合物
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
WO2007047724A2 (en) * 2005-10-18 2007-04-26 Aegerion Pharmaceuticals Compositions for lowering serum cholesterol and/or triglycerides
US20090042835A1 (en) * 2006-06-02 2009-02-12 Davis Roger A Compositions and methods for ameliorating hyperlipidemia
AU2007338625A1 (en) * 2006-12-21 2008-07-03 Aegerion Pharmaceuticals, Inc. Methods for treating obesity with a combination comprising a MTP inhibitor and a cholesterol absorption inhibitor
CN101686665B (zh) * 2007-04-20 2014-04-23 奥克塞拉有限公司 用于治疗眼科疾病和紊乱的苯乙烯基衍生化合物
NZ601866A (en) 2007-06-29 2013-12-20 Acucela Inc Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
EP2687208A1 (en) * 2007-09-12 2014-01-22 The Trustees of Columbia University in the City of New York Compositions and Methods for Treating Macular Degeneration
MX2010004718A (es) 2007-11-01 2010-07-28 Acucela Inc Compuestos derivados de amina para tratar enfermedades y trastornos oftalmicos.
CN101452001B (zh) * 2007-12-06 2013-07-24 王颖 化学发光磁酶免疫法定量检测rbp4试剂盒
WO2009089380A2 (en) * 2008-01-08 2009-07-16 The Trustees Of Columbia University In The City Of New York Methods for p2ry5 mediated regulation of hair growth and mutants thereof
JP5669729B2 (ja) * 2008-05-13 2015-02-12 ジェンメディカ・セラピューティックス・ソシエダッド・リミターダＧｅｎｍｅｄｉｃａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓｌ 代謝性障害を治療するのに有用なサリチレートコンジュゲート
CN101307314B (zh) * 2008-07-04 2011-12-14 中国医学科学院医学生物学研究所 重组噬菌体rbp/t7的构建及用其制备2型糖尿病疫苗的方法
US20110195420A1 (en) * 2008-10-09 2011-08-11 Merck Patent Gesellschaft Estrogen and anti-estrogen marker genes
WO2010048228A2 (en) 2008-10-20 2010-04-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
WO2010085514A1 (en) * 2009-01-22 2010-07-29 Celladon Corporation Fluorescence resonance energy transfer assays for sarco/endoplasmic reticulum calcium atpase and phospholamban
CA2755069A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
CN102421424A (zh) * 2009-03-16 2012-04-18 根梅迪卡治疗公司 用于治疗代谢性疾病的组合疗法
US20120108665A1 (en) * 2009-05-04 2012-05-03 Revision Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions
JP5723378B2 (ja) 2009-11-03 2015-05-27 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． トランスサイレチン（ｔｔｒ）を阻害する脂質製剤化組成物及び方法
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
JP5860029B2 (ja) * 2010-03-29 2016-02-16 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． トランスチレチン（ＴＴＲ）関連眼アミロイドーシスのためのｓｉＲＮＡ療法
AU2015264811A1 (en) * 2010-03-29 2016-01-07 Alnylam Pharmaceuticals, Inc. SiRNA therapy for transthyretin (TTR) related ocular amyloidosis
WO2012071369A2 (en) 2010-11-24 2012-05-31 The Trustees Of Columbia University In The City Of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
CN111265551A (zh) 2011-05-18 2020-06-12 加利福尼亚大学董事会 用于治疗视网膜疾病的组合物及方法
AU2012340159B2 (en) 2011-11-18 2017-09-07 Alnylam Pharmaceuticals, Inc. RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
WO2013166037A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of eye disorders
WO2013166041A1 (en) * 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Transthyretin ligands capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9790269B2 (en) 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
ES2700541T3 (es) 2013-03-14 2019-02-18 Univ Columbia Octahidrociclopentapirroles, su preparación y uso
EP2968304B1 (en) 2013-03-14 2018-10-10 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
US10092393B2 (en) 2013-03-14 2018-10-09 Allotex, Inc. Corneal implant systems and methods
CN104774840B (zh) * 2014-01-10 2019-09-17 中国人民解放军第三军医大学第一附属医院 基因突变体及其应用
CN106794364B (zh) 2014-04-30 2019-12-24 哥伦比亚大学董事会 取代的4-苯基哌啶及其制备和用途
EP3185957B1 (en) 2014-08-29 2022-06-01 Alnylam Pharmaceuticals, Inc. Patisiran for use in treating transthyretin mediated amyloidosis
PL3233174T3 (pl) * 2014-12-19 2021-08-30 Kemin Industries, Inc. Wewnątrzgałkowe dostarczanie bioaktywnych cząsteczek za pomocą jontoforezy
WO2016160718A1 (en) 2015-03-27 2016-10-06 University Of Washington Methods for treatment of retinal disease by photoreceptor gene expression modulation
US10449090B2 (en) 2015-07-31 2019-10-22 Allotex, Inc. Corneal implant systems and methods
DK3329002T3 (da) 2015-07-31 2021-01-11 Alnylam Pharmaceuticals Inc Transthyretin (ttr)-irna-sammensætninger og fremgangsmåder til anvendelse deraf til behandling eller forebyggelse af ttr-forbundne sygdomme
ES2992773T3 (en) 2016-04-22 2024-12-18 Viking Therapeutics Inc Use of thyroid beta-agonists
CN109641003A (zh) * 2016-04-22 2019-04-16 维京治疗股份有限公司 甲状腺β-激动剂的应用
NZ748179A (en) 2016-04-28 2025-08-29 Spark Therapeutics Inc Relative potency assay for viral vector encoding isomerohydrolases
GB201706009D0 (en) * 2017-04-13 2017-05-31 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of stargardt disease
KR20250046363A (ko) 2017-09-19 2025-04-02 알닐람 파마슈티칼스 인코포레이티드 트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법
WO2019099949A1 (en) * 2017-11-17 2019-05-23 The Regents Of The University Of California Manipulation of the retinoic acid signaling pathway
US20220184102A1 (en) * 2019-03-27 2022-06-16 University Of Virginia Patent Foundation Compositions and methods for treating age-related macular degeneration
KR102266963B1 (ko) * 2019-12-12 2021-06-18 연세대학교 산학협력단 렙틴 및 카로티노이드 관련 대사체, 및 피하지방면적을 이용한 식이 제한 후 비만의 대사적 상태를 예측하는 방법
CN112043820B (zh) * 2020-09-16 2022-06-21 易舟(上海)生物医药有限公司 一种眼用制剂及其制备方法和应用
EP4188372A1 (en) 2020-07-29 2023-06-07 Amryt Pharmaceuticals Inc. Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
CA3227852A1 (en) 2021-08-03 2023-02-09 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof
CN116570724A (zh) * 2023-05-17 2023-08-11 四川大学 一种基于肿瘤微环境激活型高尔基体靶向干扰剂的纳米粒

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US529455A (en) 1893-10-14 1894-11-20 Detachably securing gun-barrels to stocks
USRE29169E (en) 1971-02-10 1977-04-05 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
US4474878A (en) 1975-09-29 1984-10-02 Cordis Laboratories, Inc. Sandwich EIA for antigen associated with hepatitis
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4310546A (en) 1978-07-31 1982-01-12 Johnson & Johnson Novel retinoids and their use in preventing carcinogenesis
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4618485A (en) 1982-03-12 1986-10-21 International Immunoassay Laboratories, Inc. Kinetic radioimmunoassay test method and device
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4665098A (en) * 1985-03-28 1987-05-12 Mcneilab, Inc. Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4743400A (en) 1986-09-22 1988-05-10 Mcneilab, Inc. Process for preparing retinoyl chlorides
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5814612A (en) * 1991-04-09 1998-09-29 Sloan-Kettering Institute For Cancer Research Retinol derivatives and uses thereof
US6992108B1 (en) * 1991-12-18 2006-01-31 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US5591646A (en) 1992-09-02 1997-01-07 Arris Pharmaceutical Method and apparatus for peptide synthesis and screening
US5389681A (en) * 1992-10-22 1995-02-14 Ciba-Geigy Corporation Parenteral solutions for diclofenac salts
WO1994011030A1 (en) 1992-11-13 1994-05-26 The Ohio State University Research Foundation C-glycoside analogues of n-(4-hydroxyphenyl)retinamide-o-glucuronide
US5314909A (en) * 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
WO1995023512A1 (en) 1994-03-03 1995-09-08 Alexion Pharmaceuticals, Inc. Terminal complement inhibitor fusion genes and proteins
AU2191795A (en) 1994-03-23 1995-10-09 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US5427571A (en) * 1994-08-08 1995-06-27 Cor-A-Vent Incorporated Ventilated cap system for the ridge of a roof
JPH08136546A (ja) 1994-11-15 1996-05-31 Bio Sensor Kenkyusho:Kk 物質分析法
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5596011A (en) * 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
US5843884A (en) 1995-11-15 1998-12-01 Oklahoma Medical Research Foundation C9 complement inhibitor
US5866341A (en) 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
US5846220A (en) * 1996-04-30 1998-12-08 Medtronic, Inc. Therapeutic method for treatment of Alzheimer's disease
US6034211A (en) * 1996-06-03 2000-03-07 Kelly; Jeffery W. β-sheet nucleating peptidomimetics
WO1998027972A2 (en) * 1996-12-23 1998-07-02 Texas A & M University Anti-amyloidogenic agents
US5955305A (en) * 1997-04-28 1999-09-21 Incyte Pharmaceuticals, Inc. Human retinoid binding protein
US5776915A (en) * 1997-08-12 1998-07-07 Clarion Pharmaceuticals Inc. Phosphocholines of retinoids
CN1275911A (zh) * 1997-08-15 2000-12-06 杜克大学 一种预防或治疗雌激素依赖性疾病及失调的方法
US6100090A (en) 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
CA2356133C (en) * 1998-12-17 2006-03-14 Diversi-Plast Products, Inc. Ridge cap vent
US6343257B1 (en) 1999-04-23 2002-01-29 Peptor Ltd. Identifying pharmacophore containing combinations of scaffold molecules and substituents from a virtual library
US6128870A (en) * 1999-05-24 2000-10-10 Kohler; Raymond L. Roof vent system
CO5200852A1 (es) * 1999-09-14 2002-09-27 Lilly Co Eli Moduladores rxr con mejorado perfil farmacologico ceptores x de los retinoides
AU3082901A (en) * 1999-11-23 2001-06-04 Gerhart Graupner Modulation of signal transduction
US6450882B1 (en) * 2000-08-30 2002-09-17 Liberty Diversified Industries, Inc. Precipitation resistant ridge vent
US20020031539A1 (en) * 2000-08-30 2002-03-14 The Brigham And Women's Hospital, Inc. Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma
US20030032078A1 (en) * 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
EP1390343B1 (en) * 2001-05-29 2009-10-14 Chebigen Co., Ltd. Novel retinoid derivatives and an anti-cancer pharmaceutical composition comprising said compounds
EP1404672B1 (en) * 2001-06-22 2006-01-18 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003007944A1 (en) * 2001-07-20 2003-01-30 Qlt, Inc. Treatment of macular edema with photodynamic therapy
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US20040014131A1 (en) * 2002-07-09 2004-01-22 Pfizer Inc. Assay methods
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US20060151574A1 (en) * 2002-11-29 2006-07-13 Gpc Biotech Ag Formulations useful against hepatitis C virus infections
FI20030426A7 (fi) * 2003-03-24 2004-09-25 Jaervinen Tomi Syklodekstriinikompleksit
JP4869942B2 (ja) * 2003-12-11 2012-02-08 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド インスリン感受性／抵抗性、糖尿病および肥満におけるｒｂｐ４
US7566808B2 (en) * 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
EP1727529B1 (en) * 2004-03-17 2016-03-02 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
EP2397131B1 (en) * 2004-06-18 2019-09-11 University of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
GEP20084520B (en) * 2004-06-23 2008-10-27 Sirion Therapeutics Inc Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
CA2574466A1 (en) * 2004-07-22 2006-02-02 Vanda Pharmaceuticals, Inc. Treatment for ocular disease
CA2575265A1 (en) * 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat ophthalmic disorders
CA2584396A1 (en) * 2004-11-04 2006-05-18 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation
CN102240278A (zh) * 2004-12-08 2011-11-16 矫正诊疗公司 治疗与视黄醇有关的疾病的方法、分析和组合物
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding

Also Published As

Publication number Publication date
AU2010200842A1 (en) 2010-04-01
EP1827407A2 (en) 2007-09-05
US20060135460A1 (en) 2006-06-22
EA200701828A1 (ru) 2008-02-28
AU2005314039A1 (en) 2006-06-15
NO20073510L (no) 2007-09-06
CA2584845C (en) 2009-02-17
JP4178281B2 (ja) 2008-11-12
US20120309835A1 (en) 2012-12-06
AU2005314039B2 (en) 2008-01-31
GB2421433B (en) 2008-01-02
IL182837A0 (en) 2008-04-13
EP1827407A4 (en) 2008-05-21
JP2012097083A (ja) 2012-05-24
BRPI0518616A (pt) 2008-01-15
AU2007229394B9 (en) 2010-02-18
CA2638753A1 (en) 2006-06-15
CN101129344A (zh) 2008-02-27
JP2008523080A (ja) 2008-07-03
GB0525041D0 (en) 2006-01-18
SG144145A1 (en) 2008-07-29
KR100890410B1 (ko) 2009-03-26
CA2584845A1 (en) 2006-06-15
KR100971695B1 (ko) 2010-07-23
US20120202885A1 (en) 2012-08-09
CN101072555A (zh) 2007-11-14
EA010827B1 (ru) 2008-12-30
NO20075018L (no) 2007-09-06
NZ554734A (en) 2009-03-31
GB2421433A (en) 2006-06-28
AU2007229394B2 (en) 2009-12-10
IL185761A0 (en) 2008-01-20
EP1930046A1 (en) 2008-06-11
CN101072555B (zh) 2011-06-29
MX2007006245A (es) 2007-07-25
AU2007229394A1 (en) 2007-11-08
CN102240278A (zh) 2011-11-16
WO2006063128A3 (en) 2006-08-17
LV13666B (en) 2008-07-20
KR20070086074A (ko) 2007-08-27
WO2006063128A2 (en) 2006-06-15
GEP20094644B (en) 2009-03-10
KR20070102591A (ko) 2007-10-18
EP2289500A1 (en) 2011-03-02
BRPI0520207A2 (pt) 2012-09-25
EA011154B1 (ru) 2009-02-27
JP2008179648A (ja) 2008-08-07
NZ561148A (en) 2008-12-24

Similar Documents

Publication Publication Date Title
EA200701218A1 (ru) Композиция для лечения ретинол-ассоциированных заболеваний
EA201000787A1 (ru) Антигенсвязывающие белки
EA201100654A1 (ru) Соединения для лечения офтальмологических заболеваний и расстройств
EA200801842A1 (ru) Антитела против бета-амилоидного пептида
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
EA201590370A1 (ru) Антитела к pcsk9 c ph-зависимыми характеристиками связывания
EA200501607A1 (ru) Замещённые фенилалкановые кислоты
EA201001204A1 (ru) Методы и композиции, в которых применяют слитые полипептиды klotho-fgf
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
UY35195A (es) Composiciones y metodos para proteinas de accion prolongada
EA201790267A1 (ru) Новые модуляторы киназ
EA200600254A1 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
NO20080718L (no) Preparat for behandling av oftalmiske lidelser via serumretinol, serumretinol-bindingsprotein (RBP) og/eller serumretinol-RBP-modulering
EA200970435A1 (ru) Лечение общих расстройств развития
EA202192625A1 (ru) Лиганды псевдокиназы tyk2
EA200702656A1 (ru) Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение
TW200630327A (en) Substituted phenylalkanoic acids
DE602006019948D1 (de) Koppelten rezeptors zur behandlung von makuladegeneration
CY1112620T1 (el) Συνθεσεις οι οποιες περιλαμβανουν πεπτιδια βασικης πρωτεϊνης της μυελινης και ιατρικες χρησεις αυτων
WO2005115478A3 (en) Methods and compositions for autism spectrum disorders
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo
EA201992626A1 (ru) Способы и композиции для лечения аллергических заболеваний глаз

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU